Qiagen's Experience Developing KRAS CDx for Erbitux Yields Lessons for Rx/Dx Development | GenomeWeb

Originally published Nov. 16.

BOSTON – Although Qiagen is now a key diagnostic development partner for pharma companies looking to advance personalized treatments, the firm's road to launching its first companion test earlier this year wasn't without its perils. In light of this, Qiagen's experience commercializing the diagnostic, a KRAS test to identify best responders to the colorectal cancer drug Erbitux, offers valuable lessons for future personalized medicine collaborations between drug and diagnostic firms, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.